File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.coi.2017.07.016
- Scopus: eid_2-s2.0-85028698905
- PMID: 28865357
- WOS: WOS:000416299500011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Check point inhibitors as therapies for infectious diseases
Title | Check point inhibitors as therapies for infectious diseases |
---|---|
Authors | |
Issue Date | 2017 |
Citation | Current Opinion in Immunology, 2017, v. 48, p. 61-67 How to Cite? |
Abstract | © 2017 The recent successes of immune check point targeting therapies in treating cancer patients has driven a resurgence of interest in targeting these pathways in chronically infected patients. While still in early stages, basic and clinical data suggest that blockade of CTLA-4 and PD-1 can be beneficial in the treatment of chronic HIV, HBV, and HCV infection, as well as other chronic maladies. Furthermore, novel inhibitory receptors such as Tim-3, LAG-3, and TIGIT are the potential next wave of check points that can be manipulated for the treatment of chronic infection. Blockade of these pathways influences more than simply T cell responses, and may provide new therapeutic options for chronically infected patients. |
Persistent Identifier | http://hdl.handle.net/10722/293042 |
ISSN | 2023 Impact Factor: 6.6 2023 SCImago Journal Rankings: 2.841 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cox, Maureen A. | - |
dc.contributor.author | Nechanitzky, Robert | - |
dc.contributor.author | Mak, Tak W. | - |
dc.date.accessioned | 2020-11-17T14:57:45Z | - |
dc.date.available | 2020-11-17T14:57:45Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Current Opinion in Immunology, 2017, v. 48, p. 61-67 | - |
dc.identifier.issn | 0952-7915 | - |
dc.identifier.uri | http://hdl.handle.net/10722/293042 | - |
dc.description.abstract | © 2017 The recent successes of immune check point targeting therapies in treating cancer patients has driven a resurgence of interest in targeting these pathways in chronically infected patients. While still in early stages, basic and clinical data suggest that blockade of CTLA-4 and PD-1 can be beneficial in the treatment of chronic HIV, HBV, and HCV infection, as well as other chronic maladies. Furthermore, novel inhibitory receptors such as Tim-3, LAG-3, and TIGIT are the potential next wave of check points that can be manipulated for the treatment of chronic infection. Blockade of these pathways influences more than simply T cell responses, and may provide new therapeutic options for chronically infected patients. | - |
dc.language | eng | - |
dc.relation.ispartof | Current Opinion in Immunology | - |
dc.title | Check point inhibitors as therapies for infectious diseases | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.coi.2017.07.016 | - |
dc.identifier.pmid | 28865357 | - |
dc.identifier.scopus | eid_2-s2.0-85028698905 | - |
dc.identifier.volume | 48 | - |
dc.identifier.spage | 61 | - |
dc.identifier.epage | 67 | - |
dc.identifier.eissn | 1879-0372 | - |
dc.identifier.isi | WOS:000416299500011 | - |
dc.identifier.issnl | 0952-7915 | - |